A major new all-island radiotherapy trial, INSPIRE, will launch this Spring.
Sponsored by Cancer Trials Ireland, and supported by the Irish Research Radiation Oncology Group, the study aims to reduce treatment side-effects while maintaining excellent cancer control for men with prostate cancer.
With more than 5,000 men diagnosed with prostate cancer across the island of Ireland each year, there is a clear need to continue improving treatment and reducing its impact on quality of life. The trial plans to recruit more than 130 patients across Ireland.
The INSPIRE trial is for men with localised prostate cancer who are suitable for treatment with Stereotactic Ablative Radiotherapy (SABR).
We were joined on The Agenda this morning by Angela Clayton-Lea, CEO of Cancer Trials Ireland & Ashbourne native, who told us more about this.
We were also joined by Martin Sweeney, who was diagnosed with prostate cancer and was involved in the design of the trials.
Hosted on Acast. See acast.com/privacy for more information.